美国 FDA 授予再鼎医药靶向 DLL3 抗体药物偶联物 Zocilurtatug Pelitecan(Zoci)孤儿药资格认定,用于治疗神经内分泌癌(NEC)

美通社
Aug 04

神经内分泌癌是一类高侵袭性恶性肿瘤,预后差且治疗选择有限,存在重大未被满足的临床需求 继欧洲药品管理局授予 zoci 孤儿药资格认定(ODD)用于治疗肺神经内分泌癌之后,此次获美国 FDA 授予ODD,进一步印证了 zoci 在各类神经内分泌癌领域具有同类首创潜力 中国上海和美国马萨诸塞州剑桥2026年8月4日 /美通社/ -- 再鼎医药有限公司(纳斯达克股票代码:ZLAB;香港联交所股份代号:...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10